Food, Drugs, Healthcare, Life Sciences

A few early federal and appellate court rulings have dismissed class action lawsuits seeking to challenge health plan exclusions for weight-loss medications, with some judges...

On April 2, 2026, President Trump signed a proclamation implementing tariffs on certain pharmaceutical products pursuant to Section 232 of the Trade Expansion Act of 1962 (19 U.S.C. § 1862).

Welcome to your monthly legal insights on the trends impacting the Retail, Hospitality, and Food & Beverage Industries.

On April 2, 2026, President Trump signed a proclamation implementing tariffs on certain pharmaceutical products pursuant to Section 232 of the Trade Expansion Act of 1962 (19 U.S.C. § 1862).

On April 2, 2026, exactly one year after the “Liberation Day” tariffs, President Donald Trump issued a Proclamation, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States,” (the “Proclamation”) imposing sweeping tariffs on imported patented medications and active pharmaceutical ingredients (“APIs”).

On March 30, 2026, the Food and Drug Administration (FDA) published a final guidance entitled "Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle."

On April 2, 2026, President Trump signed two presidential proclamations invoking Section 232 of the Trade Expansion Act of 1962 and Section 604 of the Trade Act of 1974 to impose significant new tariffs on imports ...

A few early federal and appellate court rulings have dismissed class action lawsuits seeking to challenge health plan exclusions for weight-loss medications, with some judges...

The Pharmacy Benefit Management (PBM) Working Group is moving toward a more robust, standardized PBM examination and oversight framework—expanding focus to affiliated entities...